Abul, 1,687 patient aspirin prophylaxis study: 33% lower mortality [p=0.03] and 20% lower hospitalization [p=0.13] https://c19p.org/abul
copied to clipboard
Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes
et al., medRxiv, doi:10.1101/2022.08.03.22278392 (Preprint)
Retrospective 1,687 nursing home residents in the USA, showing significantly lower risk of mortality with chronic low-dose aspirin use. Low dose 81mg aspirin users had treatment ≥10 of 14 days prior to the positive COVID date, control patients had no aspirin use in the prior 14 days.
|
risk of death, 33.0% lower, HR 0.67, p = 0.03, treatment 46 of 511 (9.0%), control 201 of 1,176 (17.1%), Cox proportional hazards, day 56.
|
|
risk of death, 40.0% lower, HR 0.60, p = 0.01, treatment 33 of 511 (6.5%), control 154 of 1,176 (13.1%), Cox proportional hazards, day 30.
|
|
risk of hospitalization, 20.0% lower, HR 0.80, p = 0.13, treatment 103 of 511 (20.2%), control 352 of 1,176 (29.9%), Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Abul et al., 8/4/2022, retrospective, USA, preprint, mean age 72.3, 10 authors, study period 13 December, 2020 - 18 September, 2021.
Contact:
yasin_abul@brown.edu.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.